Fibrogen Inc CS (FGEN)

$9.71 +0.69 (7.65%)
Market Cap 39.28M
Revenue (ttm) 29.62M
Net Income (ttm) -47.58M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -160.63%
Debt to Equity Ratio 0.00
Volume 34,200
Avg Vol 36,202
Day's Range N/A - N/A
Shares Out 4.05M
Stochastic %K 97%
Beta 0.77
Analysts Sell
Price Target $43.00

Company Profile

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 978 1200
Fax: 415 978 1902
Address:
350 Bay Street, Suite 10 #6009, San Francisco, United States
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Mar. 21 at 11:26 AM
$FGEN Quick update on roxadustat Phase 3 MDS: Protocol submitted in December 2025. On the March 16 earnings call CEO confirmed we’re now inside the official 60–90 day FDA review window, with feedback expected “in the coming weeks”. Realistic timeline: late March to mid-May 2026 (highest probability April to early May). This is the next big catalyst before H2 2026 trial start. Anyone else watching this window closely? 🚀
1 · Reply
MaxMiamiFl
MaxMiamiFl Mar. 19 at 5:42 PM
$FGEN Nothing until 2H 2026. ...............HOLD is the game for now.
0 · Reply
mjtwins16
mjtwins16 Mar. 18 at 7:46 PM
$FGEN https://www.nature.com/articles/s41390-026-04832-9
1 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Mar. 18 at 3:36 PM
$FGEN https://www.ainvest.com/news/kyntra-bio-fg-3246-validation-de-risked-path-2026-interim-trial-results-2603/
1 · Reply
Astrobro
Astrobro Mar. 17 at 10:52 PM
$FGEN So am I right that this stock $KYNB trades at less than half of their cash? And they have an interim ph2 readout for prostate cancer late 2026?
2 · Reply
MaxMiamiFl
MaxMiamiFl Mar. 17 at 2:49 PM
$FGEN jesus!!
0 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Mar. 17 at 1:35 PM
$FGEN https://www.labiotech.eu/best-biotech/prostate-cancer-companies/
0 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Mar. 17 at 1:31 PM
$FGEN https://www.eurekalert.org/news-releases/1120085
0 · Reply
MaxMiamiFl
MaxMiamiFl Mar. 16 at 11:32 PM
$FGEN nothing but bla bla bla bla bla again. Repeating same story that we sold for 250m....how long they going to keep playing that same song
1 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 16 at 8:21 PM
$FGEN Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$3.51 down -178.70% YoY • Reported revenue of $1.28M up 101.04% YoY • Kyntra Bio anticipates continued significant expenses and operating losses for the foreseeable future, requiring substantial additional funding for ongoing operations, and expects a $125M payment cap by 2031 under a revenue interest financing agreement.
0 · Reply
Latest News on FGEN
No data available.
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Mar. 21 at 11:26 AM
$FGEN Quick update on roxadustat Phase 3 MDS: Protocol submitted in December 2025. On the March 16 earnings call CEO confirmed we’re now inside the official 60–90 day FDA review window, with feedback expected “in the coming weeks”. Realistic timeline: late March to mid-May 2026 (highest probability April to early May). This is the next big catalyst before H2 2026 trial start. Anyone else watching this window closely? 🚀
1 · Reply
MaxMiamiFl
MaxMiamiFl Mar. 19 at 5:42 PM
$FGEN Nothing until 2H 2026. ...............HOLD is the game for now.
0 · Reply
mjtwins16
mjtwins16 Mar. 18 at 7:46 PM
$FGEN https://www.nature.com/articles/s41390-026-04832-9
1 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Mar. 18 at 3:36 PM
$FGEN https://www.ainvest.com/news/kyntra-bio-fg-3246-validation-de-risked-path-2026-interim-trial-results-2603/
1 · Reply
Astrobro
Astrobro Mar. 17 at 10:52 PM
$FGEN So am I right that this stock $KYNB trades at less than half of their cash? And they have an interim ph2 readout for prostate cancer late 2026?
2 · Reply
MaxMiamiFl
MaxMiamiFl Mar. 17 at 2:49 PM
$FGEN jesus!!
0 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Mar. 17 at 1:35 PM
$FGEN https://www.labiotech.eu/best-biotech/prostate-cancer-companies/
0 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Mar. 17 at 1:31 PM
$FGEN https://www.eurekalert.org/news-releases/1120085
0 · Reply
MaxMiamiFl
MaxMiamiFl Mar. 16 at 11:32 PM
$FGEN nothing but bla bla bla bla bla again. Repeating same story that we sold for 250m....how long they going to keep playing that same song
1 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 16 at 8:21 PM
$FGEN Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$3.51 down -178.70% YoY • Reported revenue of $1.28M up 101.04% YoY • Kyntra Bio anticipates continued significant expenses and operating losses for the foreseeable future, requiring substantial additional funding for ongoing operations, and expects a $125M payment cap by 2031 under a revenue interest financing agreement.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 16 at 8:21 PM
$FGEN Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$3.51 down -178.70% YoY • Reported revenue of $1.28M up 101.04% YoY • Kyntra Bio anticipates incurring significant expenses and operating losses for the foreseeable future, expecting revenues to fluctuate due to uncertain timing of collaboration payments and sales, with a $125.0 million payment cap from Astellas by 2031.
0 · Reply
Hanse2014
Hanse2014 Mar. 16 at 8:14 PM
$FGEN I would prefer as well a buyout or merge
3 · Reply
MaxMiamiFl
MaxMiamiFl Mar. 16 at 7:02 PM
$FGEN LETS GO!!! MERGE!!! SELL!!!! DO SOMETHING!!!!
0 · Reply
Hanse2014
Hanse2014 Mar. 16 at 5:33 PM
$FGEN Investor and Media links are not working. Earnings today? https://www.kyntrabio.com/home
1 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Mar. 16 at 6:37 AM
$FGEN Found four fresh papers on roxadustat/HIF-PHI that keep building the scientific momentum: One MDS review highlights roxadustat as a promising oral option for anemia in personalized MDS treatment, while a brain pathway review lists it among established clinical HIF-PHIs. A hepatocellular carcinoma study shows that selective HIF activation (like roxadustat) appears safer and may even slow cancer progression compared to non-selective ones. Finally, a bone regeneration study demonstrates roxadustat-loaded hydrogel significantly boosts angiogenesis and osteogenesis with low toxicity — another strong “multi-tasker” proof for long-term value. Overall, nothing immediate for FDA, but the steady flow of positive preclinical and review data is exactly what we want to see before Phase 3 MDS launch. 🚀
0 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Mar. 16 at 6:37 AM
$FGEN https://www.researchgate.net/publication/401889234_Selective_and_Non-Selective_Pharmacological_Activation_of_Hypoxia-Inducible_Factor_Differentially_Modulate_Cancer_Progression_of_Hepatocellular_Carcinoma_Cell_Line_HepG2
0 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Mar. 16 at 6:37 AM
$FGEN https://pmc.ncbi.nlm.nih.gov/articles/PMC12982141/
0 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Mar. 16 at 6:32 AM
$FGEN https://www.sciencedirect.com/science/article/abs/pii/S0141813026002540
0 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Mar. 16 at 6:32 AM
$FGEN https://pmc.ncbi.nlm.nih.gov/articles/PMC12978835/
0 · Reply
MaxMiamiFl
MaxMiamiFl Mar. 13 at 4:48 PM
$FGEN no signs of improvement. Dammmmm!!!
0 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Mar. 12 at 8:51 AM
$FGEN https://www.marketscreener.com/news/kyntra-bio-corporate-presentation-a-march-2026-ce7e5fdcdc8ef226
3 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Mar. 10 at 9:12 AM
$FGEN A phase III study reported a significantly higher response rate for roxadustat compared to placebo, with roxadustat effectively raising hemoglobin levels ... https://karger.com/ajn/article-pdf/doi/10.1159/000551113/4514639/000551113.pdf
0 · Reply